Screening & staging of colorectal cancer
© Schima and Graser; licensee BioMed Central Ltd. 2014
Published: 9 October 2014
In Europe, colorectal cancer (CRC) is the second most common cancer, and the second most common cause of death from cancer . The vast majority of CRC develop from benign precursor lesions, so-called adenomatous polyps, which via the adenoma-carcinoma pathway may eventually transform into colon cancer. It has been shown that endoscopic removal of adenomas interrupts this pathway and subsequently reduces CRC incidence and cancer-related mortality. Thus endoscopic CRC screening programs have been instituted in many countries to reduced CRC cancer mortality. However, limited availability of colonoscopy and limited adherence of the population to colonoscopy-based screening programs is well documented. CT colonography (CTC) has evolved as an effective tool to detect small colorectal polyps, with a high sensitivity to diagnose adenomas ≥ 10 mm and advanced adenomas (with dysplasia) . After negative screening CTC, clinically presenting CRC is rare in the 5 years following CTC .
Guidelines for staging of CRC have been developed by the European Society of Medical Oncology (ESMO) , which recommend MRI and/or endorectal ultrasound for local staging of rectal cancer (in order to decide which patients need neoadjuvant therapy). MRI is preferred in stenotic tumors or cancers in the upper third of the rectum. In patients with colon cancer, local staging (by CT) primarily seeks to exclude T4 disease with infiltration into other organs. Variability exists in different European countries regarding the use of contrast-enhanced MDCT of the abdomen and chest (to be preferred over chest X-ray) for evaluation of nodal disease and distant metastases. Assessment of lymph nodes based on size criteria alone has some limitations, because metastases can be found even in normal-sized lymph nodes [5, 6]. FDG-PET is not recommended for staging . It might be used for staging of patients with CT-detected synchronous liver metastases scheduled for liver surgery. However, a recent study showed that PET/CT in patients with potentially resectable liver metastases did not result in frequent change of management and did not improve overall survival . CTC screening for CRC will be presented and CRC staging by MDCT and MRI will be highlighted.
- Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18: 581–592.PubMedView ArticleGoogle Scholar
- De Haan MC, van Gelder RE, Graser A, Bipat S, Stoker J: Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis. Eur Radiol 2011, 21: 1747–1763. 10.1007/s00330-011-2104-8PubMed CentralPubMedView ArticleGoogle Scholar
- Kim DH, Pooler BD, Weiss JM, Pickhardt PJ: Five year colorectal cancer outcomes in a large negative CT colonography screening cohort. Eur Radiol 2012, 22: 1488–1494. 10.1007/s00330-011-2365-2PubMed CentralPubMedView ArticleGoogle Scholar
- Schmoll HJ, Van Cutsem E, Stein A, et al.: ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012, 23: 2479–2516. 10.1093/annonc/mds236PubMedView ArticleGoogle Scholar
- Lahaye MJ, Beets GL, Engelen SM, et al.: Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part II. What are the criteria to predict involved lymph nodes? Radiology 2009, 252: 81–91. 10.1148/radiol.2521081364PubMedView ArticleGoogle Scholar
- Beets-Tan RG, Lambregts DM, Maas M, et al.: Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2013, 23: 2522–3125. 10.1007/s00330-013-2864-4PubMedView ArticleGoogle Scholar
- Moulton CA, Gu CS, Law CH, et al.: Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA 2014, 311: 1863–1869. 10.1001/jama.2014.3740PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.